Dulaglutide vs Spironolactone: side-by-side comparison
Dulaglutide (GLP-1 receptor agonist) and Spironolactone (Potassium-sparing diuretic / aldosterone antagonist) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Dulaglutide | Spironolactone |
|---|---|---|
| Therapeutic class | GLP-1 receptor agonist | Potassium-sparing diuretic / aldosterone antagonist |
| CAS | 923950-08-7 | 52-01-7 |
| ATC | A10BJ05 | C03DA01 |
| Molecular weight | ~63 kDa | 416.57 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Dulaglutide and Spironolactone share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Dulaglutide acts by a different mechanism than Spironolactone, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Dulaglutide: Dulaglutide activates the GLP-1 receptor in pancreatic beta cells, stimulating glucose-dependent insulin secretion and suppressing inappropriate glucagon release from alpha cells. Spironolactone: Spironolactone competitively blocks the mineralocorticoid (aldosterone) receptor in the distal tubule of the kidney, reducing sodium reabsorption and potassium excretion.
Indications compared
Dulaglutide: The medication is approved in adults with type 2 diabetes mellitus, as monotherapy when metformin is inappropriate or as add-on therapy to other antidiabetics, to improve glycaemic control. Spironolactone: Spironolactone is approved for heart failure with reduced ejection fraction, primary hyperaldosteronism, resistant hypertension, oedema in cirrhosis or nephrotic syndrome, and certain potassium-loss states.
Safety profile
Dulaglutide: The most common adverse effects are gastrointestinal: nausea, diarrhoea, vomiting and abdominal pain, usually mild to moderate and decreasing over the first weeks of treatment. Spironolactone: Common adverse effects include hyperkalaemia (especially with renal impairment or ACE inhibitors), gynaecomastia in men, menstrual irregularities in women, and dizziness from blood pressure effects.
Frequently asked questions
Is Dulaglutide better than Spironolactone? ▾
Dulaglutide and Spironolactone are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Dulaglutide and Spironolactone be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Dulaglutide
Products with Spironolactone
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.